#1 Clinical Trials Search in Europe

Rilzabrutinib

Rilzabrutinib is an innovative drug currently being studied in clinical trials for its potential to treat a range of medical conditions. This article provides an overview of the ongoing research into rilzabrutinib’s effectiveness and safety for diseases such as immune thrombocytopenia, atopic dermatitis, asthma, and IgG4-related disease. We’ll explore the drug’s mechanism of action, its potential benefits, and what patients can expect from participating in these clinical trials.

Table of Contents

What is Rilzabrutinib?

Rilzabrutinib is a new medication being studied for the treatment of various autoimmune disorders. It is also known by other names such as PRN1008 and SAR444671[3]. Rilzabrutinib belongs to a class of drugs called BTK inhibitors, which work by targeting a specific protein in the body involved in the immune system’s function[2].

How Rilzabrutinib Works

Rilzabrutinib works by inhibiting an enzyme called Bruton’s Tyrosine Kinase (BTK). This enzyme plays a crucial role in the development and function of certain immune cells. By blocking BTK, rilzabrutinib can help reduce the overactive immune response that occurs in autoimmune diseases[1]. This mechanism of action makes rilzabrutinib a potential treatment for various conditions where the immune system mistakenly attacks the body’s own tissues.

Conditions Treated with Rilzabrutinib

Rilzabrutinib is being studied for several autoimmune conditions, including:

  • Immune Thrombocytopenia (ITP): A disorder where the immune system attacks and destroys platelets, leading to easy bruising and bleeding[2][4].
  • Warm Autoimmune Hemolytic Anemia (wAIHA): A condition where the immune system destroys red blood cells, causing anemia[3].
  • Atopic Dermatitis: A chronic skin condition characterized by itchy, inflamed skin[5].
  • IgG4-Related Disease: A group of disorders characterized by tissue swelling and fibrosis (scarring) in various organs[6].
  • Asthma: A chronic lung condition causing breathing difficulties[7].

Clinical Trials and Research

Rilzabrutinib is currently undergoing extensive clinical trials to evaluate its safety and effectiveness in treating various autoimmune conditions. These trials are being conducted in different phases:

  • Phase 1 studies: These early studies focus on understanding how the drug is processed in the body (pharmacokinetics) and its safety profile in healthy volunteers[1][8].
  • Phase 2 studies: These trials evaluate the drug’s effectiveness and safety in patients with specific conditions, such as ITP, wAIHA, and atopic dermatitis[2][3][5].
  • Phase 3 studies: Larger trials comparing rilzabrutinib to placebo or standard treatments in conditions like ITP[4].

How Rilzabrutinib is Administered

Rilzabrutinib is typically administered as an oral medication in the form of tablets or caplets. The dosage and frequency may vary depending on the condition being treated and the specific clinical trial. Common dosing regimens include:

  • 400 mg twice daily[4]
  • 400 mg three times daily[5]

Some studies are also investigating how food affects the absorption of rilzabrutinib, which may influence how it should be taken[9].

Potential Side Effects

As with any medication, rilzabrutinib may cause side effects. The full range of potential side effects is still being studied in clinical trials. Common methods for monitoring safety include:

  • Tracking adverse events reported by patients
  • Regular blood tests to check for changes in blood cell counts and other laboratory values
  • Monitoring of vital signs and electrocardiograms (ECGs) to check heart function

It’s important to note that the safety profile of rilzabrutinib is still being established through ongoing clinical trials[4][5].

Aspect Details
Drug Name Rilzabrutinib (also known as PRN1008/SAR444671)
Drug Class BTK (Bruton’s Tyrosine Kinase) inhibitor
Administration Oral tablets or caplets
Conditions Studied Immune Thrombocytopenia (ITP), Atopic Dermatitis, Asthma, IgG4-Related Disease, Warm Autoimmune Hemolytic Anemia (wAIHA)
Common Dosages in Trials 400 mg twice daily or three times daily
Primary Outcome Measures Platelet count response, reduction in disease severity scores, safety and tolerability
Secondary Outcome Measures Quality of life improvements, reduction in rescue medication use, pharmacokinetic parameters
Safety Monitoring Adverse events, laboratory tests, vital signs, ECG results
Trial Phases Phase 1, Phase 2, and Phase 3 studies ongoing
Special Populations Some trials include both adults and adolescents

FAQ

  • What is rilzabrutinib and how does it work? Rilzabrutinib is an oral medication that belongs to a class of drugs called BTK inhibitors. It works by blocking a specific protein in the body called Bruton's tyrosine kinase (BTK), which is involved in certain immune system processes. By inhibiting BTK, rilzabrutinib may help regulate the immune response in various conditions.
  • What conditions is rilzabrutinib being studied for? Rilzabrutinib is currently being investigated in clinical trials for several conditions, including immune thrombocytopenia (ITP), atopic dermatitis, asthma, IgG4-related disease, and warm autoimmune hemolytic anemia (wAIHA).
  • How is rilzabrutinib administered in clinical trials? In most clinical trials, rilzabrutinib is administered orally as tablets or caplets. The dosage and frequency may vary depending on the specific study, but common dosing regimens include 400 mg twice daily or three times daily.
  • What are the potential benefits of rilzabrutinib? Potential benefits of rilzabrutinib include improved platelet counts in ITP, reduced symptoms in atopic dermatitis and asthma, and better control of disease activity in IgG4-related disease. However, the full extent of its benefits is still being determined through clinical trials.
  • Are there any known side effects of rilzabrutinib? As with any medication in clinical trials, the full safety profile of rilzabrutinib is still being established. Researchers are closely monitoring for any adverse events during the studies. Common methods of assessing safety include tracking treatment-emergent adverse events, laboratory tests, vital signs, and electrocardiogram (ECG) results.

Ongoing Clinical Trials on Rilzabrutinib

  • Study of oral rilzabrutinib for adults with immune thrombocytopenia who did not respond to first-line treatment

    Recruiting

    1 1 1
    Investigated drugs:
    Austria Czechia France Germany Hungary Italy +2

  • Study of rilzabrutinib tablets compared to placebo in adults with warm autoimmune hemolytic anemia

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Austria Czechia Denmark Germany Greece Hungary +5

  • Study on the Effects and Safety of Rilzabrutinib for Adults with Graves’ Disease

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy Spain

  • Study on Rilzabrutinib for Patients Aged 10-65 with Sickle Cell Disease

    Recruiting

    1 1
    Investigated drugs:
    Belgium France Germany Greece Italy The Netherlands +1

  • Study of Rilzabrutinib for Adults with Relapsed Immune Thrombocytopenia

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia The Netherlands

  • Study on the Effects and Safety of Rilzabrutinib for Adults with Warm Autoimmune Hemolytic Anemia

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Denmark Italy Spain

  • Study on the Safety and Effectiveness of Rilzabrutinib for Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia (ITP)

    Not recruiting

    1 1
    Investigated drugs:
    France Germany Hungary Italy Norway Poland +1

Glossary

  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion. PK studies help researchers understand how the body processes the medication.
  • Bruton's Tyrosine Kinase (BTK): An enzyme that plays a crucial role in the development and functioning of various types of blood cells, particularly B cells. BTK is the target of rilzabrutinib.
  • Immune Thrombocytopenia (ITP): A blood disorder characterized by a low platelet count, which can lead to easy bruising and bleeding. Platelets are blood cells that help with clotting.
  • Atopic Dermatitis: A chronic, inflammatory skin condition characterized by itchy, red, and dry skin. It is a type of eczema that can significantly impact quality of life.
  • IgG4-Related Disease: A chronic inflammatory condition that can affect multiple organs, characterized by elevated levels of IgG4 antibodies and the formation of tumor-like masses.
  • Warm Autoimmune Hemolytic Anemia (wAIHA): A rare blood disorder where the immune system mistakenly destroys red blood cells, leading to anemia.
  • Eczema Area and Severity Index (EASI): A tool used to measure the extent and severity of atopic dermatitis, considering factors such as redness, thickness, scratching, and the affected body surface area.
  • Investigator's Global Assessment (IGA): A scale used by researchers to assess the overall severity of a skin condition, typically used in dermatology clinical trials.
  • Peak Pruritus Numerical Rating Scale (PP-NRS): A scale used to measure the intensity of itching experienced by patients, typically ranging from 0 (no itch) to 10 (worst itch imaginable).
  • Forced Expiratory Volume in One Second (FEV1): A measure of lung function that represents the amount of air a person can forcefully exhale in one second. It is often used to assess the severity of asthma and other respiratory conditions.

References

  1. https://clinicaltrials.gov/study/NCT06444191
  2. https://clinicaltrials.gov/study/NCT03395210
  3. https://clinicaltrials.eu/trial/study-on-the-effects-and-safety-of-rilzabrutinib-for-adults-with-warm-autoimmune-hemolytic-anemia/
  4. https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-rilzabrutinib-for-adults-and-adolescents-with-persistent-or-chronic-immune-thrombocytopenia-itp/
  5. https://clinicaltrials.gov/study/NCT05018806
  6. https://clinicaltrials.gov/study/NCT04520451
  7. https://clinicaltrials.gov/study/NCT05104892
  8. https://clinicaltrials.gov/study/NCT06444204
  9. https://clinicaltrials.gov/study/NCT04748926